Therefore, we detect the serum DKK1 level in pediatric patients with OI and analyze its relationship with BMD, fracture incidence, bone turnover makers, and the pathogenic genotype of OI, and to determine whether DKK1 has value as a novel biomarker and therapeutic target of OI. Here, DKK1 is linked to osteogenesis imperfecta.